Landscape Capital Management L.L.C. Invests $884,000 in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Landscape Capital Management L.L.C. purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 8,188 shares of the medical equipment provider’s stock, valued at approximately $884,000.

Several other hedge funds have also bought and sold shares of the company. Ashton Thomas Securities LLC bought a new stake in shares of Zimmer Biomet during the 3rd quarter worth about $28,000. Bangor Savings Bank acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth $31,000. Family Firm Inc. bought a new position in shares of Zimmer Biomet in the second quarter worth $33,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Zimmer Biomet in the second quarter valued at about $43,000. Finally, Ridgewood Investments LLC bought a new stake in Zimmer Biomet during the second quarter worth about $43,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Wolfe Research assumed coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They set a “peer perform” rating for the company. Canaccord Genuity Group reduced their price objective on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday, September 10th. Wells Fargo & Company increased their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Raymond James decreased their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $123.22.

Zimmer Biomet Stock Up 1.7 %

Shares of NYSE:ZBH opened at $110.23 on Friday. The business has a fifty day simple moving average of $106.79 and a 200 day simple moving average of $109.78. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The firm has a market cap of $21.94 billion, a P/E ratio of 20.96, a P/E/G ratio of 1.99 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.65 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend was Monday, September 30th. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.